Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alzheimer’s Biomarker Development Hampered By ‘Limited’ Commercial Incentives

Executive Summary

Eli Lilly executive suggests the public sector may need to come up with a solution to drive innovation if the private sector does not do so.

You may also be interested in...



As US FDA Settles Into Teleworking, Will Application Reviews Be Affected?

Productivity may suffer under coronavirus-mandated telework despite workforce diligence, experts say.

US FDA Freezes Inspections And Outside Meetings. Will Review Goal Dates Stay Put?

Sponsors have been asked to switch to teleconferences with FDA staff as the agency prepares for more of its employees to work from home.

Alzheimer’s Drug Coverage Issues Move To Forefront With Biogen’s Plan To Seek Approval

Any product would be mostly covered by Medicare, but because the potential patient population will likely be 'substantial,' payers will likely 'closely scrutinize' these drugs, Duke Margolis white paper observes.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel